Article

How is migraine associated with cardiovascular and cerebrovascular events?


 

Key clinical point: Patients with migraine are at an increased risk of myocardial infarction (MI) and stroke, and those with migraine with aura are also at an increased risk of overall cardiovascular mortality.

Main finding: Migraine showed a positive association with MI (hazard ratio [ HR] 1.36; P < .001), unspecified stroke (HR 1.30; P = .01), ischemic stroke (HR 1.35; P = .03), and hemorrhagic stroke (HR 1.43; P = .02). Migraine with aura was positively associated with cardiovascular mortality (HR 1.27; P < .001).

Study details: Findings are from a meta-analysis of 18 prospective cohort studies including 362,434 patients with migraine and 1,323,714 control participants.

Disclosures: BYQ Tan declared receiving the Ministry of Health Healthcare Research Scholarship, Singapore, and the Chan Heng Leong Research Award. CH Sia received financial support from the National University of Singapore Yong Loo Lin School of Medicine’s Junior Academic Faculty Scheme. The authors declared no competing interests.

Source: Ng CYH et al. J Neurol. 2022 (Jan 8). Doi: 10.1007/s00415-021-10930-x.

Recommended Reading

Fremanezumab effective and safe in older patients with chronic or episodic migraine
Migraine ICYMI
Ubrogepant beneficial in migraine regardless of prior preventive medication use
Migraine ICYMI
Clinical Edge Journal Scan Commentary: Migraine January 2022
Migraine ICYMI
Ketamine nasal spray provides slow-acting relief for cluster headache attacks
Migraine ICYMI
Erenumab is an effective therapeutic option for migraine with aura
Migraine ICYMI
Noninvasive vagus nerve stimulation affirms its potential to prevent migraine
Migraine ICYMI
Erenumab improves work output in employed patients with migraine
Migraine ICYMI
Fremanezumab efficacy against difficult-to-treat migraine is unperturbed by age or sex
Migraine ICYMI
Real-world value of fremanezumab therapy against migraine
Migraine ICYMI
Effects of pausing migraine prophylaxis with CGRP-receptor mAb hint at therapy resumption
Migraine ICYMI